Investing.com - Unicycive Therapeutics reported on Monday third quarter earnings that missed analysts' forecasts and revenue that topped expectations.
Unicycive Therapeutics announced earnings per share of $-0.37 on revenue of $951K. Analysts polled by Investing.com EPS of $-0.28 on revenue of $0.
Unicycive Therapeutics 's are down 19.03% and is trading at $0.71 , still down 77.10% from its 52 week high of $3.10 set on Wednesday, November 24, 2021.
Unicycive Therapeutics follows other major Healthcare sector earnings this month
Unicycive Therapeutics's report follows an earnings beat by J&J on Tuesday, October 18, 2022, who reported EPS of $2.55 on revenue of $23.79B, EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of $1.98 on revenue of $6.94B, for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar